Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer

Romidepsin 8 mg/m2 plus erlotinib appears well tolerated, has evidence of disease control, and exhibits effects on relevant molecular targets in an unselected advanced NSCLC population.